Skip to main content

Table 3 Multivariate analysis of prognostic factors for progression-free survival

From: Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma

Variables HR (95% CI) P value
BCLC stage
 C Reference  
 B 0.551 (0.293, 1.035) 0.064
Tumor number
  = 1 Reference  
  ≥ 2 0.601 (0.325, 1.110) 0.104
NLR 0.802 (0.657, 0.980) 0.031
  1. BCLC: Barcelona Clinic Liver Cancer; NLR: Neutrophil-to-lymphocyte ratio